4 reports

  • Market drivers
  • Neutropenia market in EMEA

A survey in Germany reported that out of the total G-CSF or filgrastim prescriptions, approximately one-fourth prescription accounted for biosimilar version of filgrastim.

  • G-CSF
  • World
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • 4.3 GRANULOCYTE - COLONY STIMULATING FACTOR (G-CSF) BIOSIMILARS MARKET

Two biosimilar approvals have been withdrawn; one for filgrastim in April 2011 and one for somatropin in May 2012, leaving a total of ## biosimilars approved for use in Europe.

  • G-CSF
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Filgrastim: Biosimilar Products in China & Taiwan - 2/2
  • Filgrastim: Biosimilar Products in Other Less Regulated Markets

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and...

  • Biosimilar
  • Filgrastim
  • G-CSF
  • United States
  • Amgen Inc.
  • filgrastim
  • FILGRASTIM - DRUG PROFILE

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2018, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Chemotherapy
  • G-CSF
  • United States
  • World
  • Product Initiative